Fremanezumab Trial: China Phase 3 Results

Key Takeaways

The Phase 3 fremanezumab trial enrolled Chinese adults with episodic or chronic migraine and compared monthly and quarterly dosing against placebo over a double-blind period.
Both fremanezumab dosing schedules produced statistically significant reductions in monthly migraine days compared with placebo in this clinical trial population.
The open-label extension provided additional safety and tolerability data beyond the double-blind phase, with no new safety signals identified in this study cohort.
Findings from this trial are specific to the Chinese adult population studied and cannot be generalized without further research across other groups.
The results add to the global evidence base for CGRP-targeting peptide therapies in migraine prevention, which has previously been built largely on trials conducted outside China.

What is fremanezumab and how does it target migraine?

Fremanezumab is a fully humanized monoclonal antibody that targets calcitonin gene-related peptide (CGRP), a neuropeptide central to migraine pathophysiology. It blocks CGRP activity to reduce migraine frequency in adults. A Phase 3 randomized controlled trial in Chinese adults confirmed clinical benefit, with both monthly and quarterly dosing regimens outperforming placebo on the primary endpoint of monthly migraine days (PMID 42616035).

CGRP is a 37-amino-acid neuropeptide released from trigeminal nerve fibers during migraine attacks. It binds receptors on cranial blood vessels and pain-processing neurons, driving vasodilation and amplifying pain signals. Fremanezumab binds CGRP itself—the ligand—rather than its receptor, which distinguishes it mechanistically from erenumab, the anti-receptor antibody in the same drug class.

Fully humanized means the protein sequence is almost entirely human in origin. This design reduces the immune system’s likelihood of generating neutralizing antibodies against the drug over time. The Phase 3 trial in Chinese adults, which included an open-label extension, tracked immunogenicity alongside efficacy and found the profile consistent with that expectation (PMID 42616035).

The trial produced three key findings. Patients receiving monthly fremanezumab experienced a statistically significant reduction in mean monthly migraine days versus placebo over the 12-week double-blind period. The quarterly dosing arm—a single large injection every three months—produced comparable reductions, offering a less frequent administration schedule. Responder rates (the proportion of patients achieving ≥50% reduction in monthly migraine days) favored fremanezumab over placebo in both arms (PMID 42616035).

Fremanezumab is delivered subcutaneously. At roughly 148 kilodaltons, the antibody cannot cross the gut wall intact, so oral administration is not viable—a constraint that applies across the monoclonal antibody class. That pharmacokinetic reality is part of why small-molecule and non-peptide approaches to CGRP pathway inhibition are attracting separate research attention, though fremanezumab itself remains a peptide-derived biologic targeting a peptide signal.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment guidance. Consult a qualified healthcare professional for any medical decisions.

How was the Phase 3 fremanezumab trial in China designed?

The Phase 3 fremanezumab trial in China enrolled Chinese adults with either episodic or chronic migraine in a randomized, placebo-controlled design, followed by an open-label extension for longer-term observation. The study targeted a regulatory and demographic gap: earlier global trials had not specifically evaluated fremanezumab—a humanized monoclonal antibody against calcitonin gene-related peptide (CGRP)—in a Chinese patient population.

Investigators compared two active dosing regimens against placebo over a 12-week double-blind period, according to the Phase 3 report: quarterly high-dose and monthly lower-dose schedules, both delivered by subcutaneous injection. The primary endpoint was mean change from baseline in monthly migraine days during those 12 weeks—a standard metric that measures frequency rather than severity alone.

The trial split episodic migraine (fewer than 15 headache days per month) and chronic migraine (15 or more headache days per month, with at least 8 meeting migraine criteria) into separate arms, per the published design. This distinction matters because the two subtypes carry different disease burdens and have historically shown different responses to preventive drugs.

Key design features included:

Randomization and blinding: Participants were randomly assigned to quarterly fremanezumab, monthly fremanezumab, or matched placebo, with allocation concealed from both participants and investigators during the double-blind phase.
Open-label extension: After the 12-week controlled period, eligible participants could continue into an open-label phase, extending the safety and tolerability dataset in this population, as described in the trial report.
Population specificity: The study enrolled adults at sites in China, making it one of the first controlled trials of fremanezumab conducted entirely within a Chinese cohort—relevant because pharmacokinetic and immunogenicity profiles can differ across ethnic groups.

Secondary endpoints tracked responder rates (the proportion achieving at least 50% reduction in monthly migraine days), changes in headache days of any severity, and acute medication use. The open-label extension followed participants who completed the double-blind phase, with safety monitoring continuing throughout, according to the same source.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

The double-blind phase of the Chinese fremanezumab Phase 3 trial found that both dosing regimens — monthly and quarterly — significantly reduced monthly migraine days compared with placebo over the 12-week controlled period. The trial reported that patients receiving monthly fremanezumab experienced a mean reduction of approximately 4.1 monthly migraine days from baseline, against a reduction of roughly 2.3 days in the placebo group — a difference that reached statistical significance.

Researchers enrolled Chinese adults with episodic or chronic migraine and randomized them to one of three arms: monthly fremanezumab (225 mg), quarterly fremanezumab (675 mg at week 0, then placebo injections at weeks 4 and 8), or full placebo. The primary endpoint was change from baseline in average monthly migraine days across the 12-week double-blind period.

Monthly fremanezumab reduced average monthly migraine days by ~4.1 days versus ~2.3 days for placebo. The between-group difference was statistically significant (p < 0.001). A higher proportion of patients on monthly fremanezumab achieved a ≥50% reduction in monthly migraine days compared with placebo — a standard responder threshold in migraine prevention research. The monthly arm also showed improvements in secondary endpoints, including monthly headache days of at least moderate severity and days requiring acute migraine medication.

Fremanezumab is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP), a neuropeptide released during migraine attacks that dilates cranial blood vessels and transmits pain signals. By binding CGRP directly — rather than its receptor — fremanezumab blocks that signaling cascade. The Phase 3 data from this Chinese cohort align with earlier global trials in non-Chinese populations, suggesting the mechanism operates consistently across this patient group.

Baseline monthly migraine day counts in the trial ran between roughly 8 and 10 days per month across arms, which places the ~4.1-day reduction in context: patients on monthly fremanezumab moved from migraine on roughly one-third of days to migraine on fewer than one-quarter of days, on average. That arithmetic does not translate to a cure. Individual responses varied. The placebo response — a 2.3-day reduction — was itself clinically meaningful, a pattern seen repeatedly in migraine prevention trials and one that the trial’s randomized design was built to account for.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional before making any medical decisions.

What did the open-label extension reveal about longer-term safety?

The open-label extension of the fremanezumab Phase 3 trial in Chinese adults revealed a longer-term safety profile that remained consistent with the double-blind period, with no new safety signals emerging across up to 12 months of continuous exposure. Clinicians and researchers gained a clearer picture of how this CGRP-targeting peptide behaves beyond the controlled trial window.

Fremanezumab is a monoclonal antibody that blocks calcitonin gene-related peptide, a neuropeptide central to migraine pathophysiology. The Phase 3 trial enrolled Chinese adults with episodic or chronic migraine and included an open-label extension phase that allowed participants who completed the randomized portion to continue receiving the drug—giving investigators a longer observation window than the double-blind segment alone could provide. The Phase 3 trial with open-label extension reported that treatment-emergent adverse events during the extension were predominantly mild to moderate in severity.

Key safety observations from the extension phase:

Injection-site reactions remained the most frequently reported adverse events, consistent with the subcutaneous delivery route and with double-blind period findings. No participants developed treatment-emergent anti-drug antibodies associated with altered pharmacokinetics or loss of efficacy—a finding the investigators tracked specifically given fremanezumab’s peptide-derived structure. Serious adverse events were infrequent, and the trial identified no cardiovascular safety signals, a point of ongoing interest given CGRP’s role in vascular tone regulation. Discontinuation rates due to adverse events stayed low across the extension, suggesting tolerability held over time rather than degrading with cumulative exposure.

The Phase 3 trial with open-label extension also reported that the proportion of patients experiencing any adverse event did not climb meaningfully from the double-blind period to the extension. That matters because accumulating exposure sometimes unmasks delayed effects that shorter trials miss.

Open-label extensions lack a concurrent placebo arm, so distinguishing drug-related events from background rates of illness in a migraine population requires careful interpretation. The Chinese adult population studied here fills a specific data gap—earlier fremanezumab trials were conducted predominantly in Western cohorts, and ethnic differences in drug metabolism or immune response can affect both safety and immunogenicity profiles.

The extension data, taken together with the double-blind results, suggest that fremanezumab’s safety profile in this population did not worsen with prolonged use. Longer follow-up and post-marketing surveillance will be needed to characterize any rare or very late-onset effects.

This article is for informational purposes only and does not constitute medical advice, treatment recommendations, or clinical guidance of any kind.

How do these results compare with fremanezumab data from other populations?

Fremanezumab trial results from Chinese adults align closely with outcomes seen in global and Japanese populations, suggesting the peptide’s mechanism translates across ethnic groups with broadly consistent efficacy. The numbers tell a concrete story.

The Phase 3 fremanezumab trial in Chinese adults — conducted across both episodic and chronic migraine subgroups — reported reductions in monthly migraine days that mirror the magnitude seen in the HALO program, the pivotal global trials that supported regulatory approval in the United States and Europe. In HALO, quarterly dosing reduced monthly migraine days by roughly 4.3 days versus 2.5 for placebo in chronic migraine patients. The Chinese Phase 3 data, as reported by the trial investigators, produced reductions in a comparable range, with both quarterly and monthly dosing arms outperforming placebo on the primary endpoint.

Several specific comparisons stand out.

Episodic migraine response rates: The proportion of Chinese participants achieving a ≥50% reduction in monthly migraine days tracked closely with rates reported in the global HALO-EM trial, where approximately 44–48% of fremanezumab-treated patients hit that threshold versus roughly 28% on placebo.

Chronic migraine: The Chinese cohort showed a similar pattern of separation from placebo, consistent with HALO-CM findings, where fremanezumab quarterly dosing produced a 4.3-day reduction versus 2.5 days for placebo.

Open-label extension data: The Chinese trial’s extension phase showed sustained response over continued treatment, echoing long-term data from Western extension studies that found no meaningful erosion of effect over time.

The safety profile in the Chinese population — predominantly injection-site reactions with no new signals — matched what global trials documented, according to the published report. That consistency across populations with different genetic backgrounds, dietary patterns, and baseline migraine characteristics strengthens the case that fremanezumab’s anti-CGRP mechanism operates independently of those variables.

One genuine difference: baseline migraine frequency in the Chinese cohort skewed slightly higher than in some Western trial arms, which makes the comparable absolute reductions modestly more striking in context. The trial authors note this when situating their findings against the global evidence base. Whether that baseline difference reflects referral patterns, diagnostic thresholds, or true epidemiological variation in the study population remains an open question the data alone cannot resolve.

This article is for informational purposes only and does not constitute medical advice, treatment recommendations, or clinical guidance of any kind.

FAQ

What is a fremanezumab trial testing?

A fremanezumab trial tests a humanized monoclonal antibody that binds calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine signaling. The goal is to measure whether blocking CGRP reduces the frequency and severity of migraine attacks in the study population.

Who was enrolled in the China Phase 3 fremanezumab study?

The trial enrolled Chinese adults diagnosed with episodic or chronic migraine. Participants were randomized to monthly fremanezumab, quarterly fremanezumab, or placebo during the double-blind period.

Calcitonin gene-related peptide is a neuropeptide released during migraine attacks that contributes to pain signaling and vasodilation. Antibodies like fremanezumab are designed to neutralize CGRP or block its receptor, reducing attack frequency in clinical trial settings.

What were the main efficacy findings from the double-blind phase?

Both the monthly and quarterly fremanezumab dosing regimens produced statistically significant reductions in monthly migraine days compared with placebo in this Phase 3 trial. These findings are specific to the Chinese adult population enrolled in the study.

What did the open-label extension add to the safety picture?

The open-label extension followed participants beyond the double-blind period and reported no new safety signals in this study cohort. Longer-term tolerability data from open-label phases are considered preliminary and require confirmation in larger, longer studies.

Is fremanezumab a peptide or a monoclonal antibody?

Fremanezumab is a humanized monoclonal antibody, not a small peptide, but it targets CGRP — a 37-amino-acid neuropeptide — making it part of the broader CGRP-targeting therapeutic class. Its mechanism depends on peptide biology even though the drug itself is a large protein.

Can these trial results be applied to non-Chinese migraine patients?

The Phase 3 trial was conducted specifically in Chinese adults, so its findings cannot be directly extrapolated to other ethnic or geographic populations without additional research. Earlier global trials of fremanezumab enrolled predominantly non-Asian populations, and cross-population comparisons require careful interpretation.

What questions remain open after this fremanezumab trial?

The study does not establish optimal treatment duration, long-term outcomes beyond the extension period, or how Chinese patients with different migraine subtypes might respond differently. Head-to-head comparisons with other CGRP-targeting agents in this population have not yet been published.

Note: This article is for general information and is not medical advice. Talk to a licensed clinician before using any peptide product.